A Phase 1/2 interventional study of Opt-IVF and control in Ivf, sponsored by Urmila DIwekar. Active, not recruiting at 1 site in United States. Open to female participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Urmila DIwekar · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 395 studies in Infertility with a site in United States — 62 open to participants now, 84 under way, 7 of them phase 3. Infertility · United States.
Among the 395 studies in Infertility with a site in United States, this one is the 122nd largest by planned enrollment of the 274 interventional ones that give a count, is one of 17 that started in 2026, is one of 5 in phase 1/2, reaches primary completion later than 27 of the 82 other live ones, and was the 394th registered.
2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →62 of the 395 studies in Infertility with a site in United States are open now. Recruiting first, the newest first:
Abigail Mancuso · Sites in United States
Ages 18–45
Brigham and Women's Hospital · Sites in United States
Ages 18–40 · Women only · Healthy volunteers
Kevin Doody · Sites in United States
Ages 18–35 · Women only
University of Oklahoma · Sites in United States
Ages 18–45 · Women only
Reproductive Medicine Associates of New Jersey · Sites in United States
Ages 18–42 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 20 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
395 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 32 · Phase 3 31 · Phase 4 35
First in 1989; this study’s year is marked. 17 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 133 across 1,415 interventional studies indexed under Infertility.
Median enrollment 84 across the 274 interventional studies, 150 across the 119 observational. Of the 252 that completed or were terminated, 57 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
91 of 395 have an industry lead sponsor. The 10 most frequent:
Urmila DIwekar is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Urmila DIwekar has 2 studies filed under Infertility — fewer than ten, so there is no comparison to draw.
25 of the studies in Infertility with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06375811Phase 3Yale UniversityPre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp | 2027-03-31 |
| NCT06858111Phase 3Gameto, Inc.Fertilo In Vitro Research Study and Trial | 2027-05 |
| NCT04544462Genomic Prediction Inc.ANXA5 M2 Haplotyping in IVF Patients and Embryos | 2026-11 |
| NCT07083700Inception Fertility Research Institute, LLCFrame Support Study | 2026-12 |
| NCT02573415The Cleveland ClinicUterine Transplantation for the Treatment of Uterine Factor Infertility | 2026-12 |
Add all 25 to your calendar (.ics) → With an account.
Among the 395 studies in Infertility with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A clinical trial will determine the effectiveness of the Opt-IVF decision-support tool in generating personalized, optimal drug-dosage profiles for each patient in the United States.
This will be a two-arm randomized clinical trial involving more than 100 patients; one arm will undergo superovulation using dosages predicted by the decision-support tool, while the other will receive the current standard treatment. The research question is whether outcomes of patient dosage treatment using Opt-IVF are better or similar to the current practice. We will compare the outcomes of the two groups of patients in terms of the numbers and percentage of mature follicles retrieved at the end of each cycle, total FSH and HMG dosages used, and the number of required testing days for that cycle, total number of M2s, Number of embryos, Number of Grade A embryos, and Number of Grade A blastocysts.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Normal Responders
Exclusion Criteria:
Opt-IVF 1.0 arm will receive personalized total-gonadotropin optimization predicted dosage per day
Device: Opt-IVF
This standard-care arm will receive physician-directed dosing
Other: control
Opt-IVF predicted dosage for IVF
Doctor prescribed dosage
Total Gonadotropin dosage
Total Dosage
Time frame: 11 days
M2 Oocytes
M2 Oocytes
Time frame: 13 days
Total Embryos
Number of Embryos
Time frame: 15 days
Grade A Blastocysts
No. of Grade A blastocysts
Time frame: 20 days
Plan to share: Yes — by contacting the PI.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: June 1, 2027
Access criteria: They can contact the PI or Opt-IVF website and they will send the requested information
Data sharing details ↗ · www.opt-ivf.com
Started Oct 2026 (actual). Primary completion is estimated for Mar 2027, 5 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Urmila DIwekar